Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227870 · ClinicalTrials.gov registry record · Phase 2
L19IL2/TNF in Patients With Basal Cell Carcinoma
A Phase 2 study, sponsored by Philogen S.p.A..
- Not yet
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT07227870 is a Phase 2 study that has not yet begun recruiting, run by Philogen S.p.A.. The registered enrollment target is 92 participants.
The verdict
NCT07227870, a Phase 2 study, has not yet begun recruiting, sponsored by Philogen S.p.A..
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Open-label, single-arm, multicentre study in patients with locally advanced BCC amenable to intratumoral injection, who have progressed on or are intolerant to systemic therapy as determined by a local multidisciplinary tumor board. The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four weekly injections may be administered as per treating physician judgement. Patients will be followed for a maximum of 160 weeks after beginning of treatment.
Interventions
- DRUG L19IL2/L19TNF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2026-02 |
| Est. Completion | 2031-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227870
The ClinicalTrials.gov registry entry for NCT07227870 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philogen S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L19IL2/L19TNF is the first listed.
NCT07227870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07227870 about?
NCT07227870 is a clinical study titled "L19IL2/TNF in Patients With Basal Cell Carcinoma". Open-label, single-arm, multicentre study in patients with locally advanced BCC amenable to intratumoral injection, who have progressed on or are intolerant to systemic therapy as determined by a local multidisciplinary tumor board. The primary objective of the study is to evaluate the activity of i...
What is the current status of trial NCT07227870?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2026-02. Estimated completion is 2031-02.
What interventions are being tested in trial NCT07227870?
The interventions under investigation include: L19IL2/L19TNF (DRUG).
Who is sponsoring clinical trial NCT07227870?
This trial is sponsored by Philogen S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.